Home CONTACT Neoplasma 2008 Neoplasma Vol.55, No.3, p.229-238, 2008

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.55, No.3, p.229-238, 2008

Title: Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism
Author: E. PAPADOPOULOU, K. ANAGNOSTOPOULOS, G. TRIPSIANIS, I. TENTES, S. KAKOLYRIS, G. GALAZIOS, E. SIVRIDIS, K. SIMOPOULOS, A. KORTSARIS

Abstract: The present study was conducted to clarify the predictive and prognostic significance of serum TGF-β1 in breast cancer in relation to Ile655Val single nucleotide polymorphism (SNP) of human epidermal growth factor receptor-2 (HER-2). In a case-control study, 56 consecutive patients with primary breast cancer were prospectively included and evaluated. The control group consisted of 45 healthy women. Serum concentrations of TGF-β1 were measured by quantitative sandwich enzyme immunoassay (ELISA). HER-2 SNP was genotyped using PCR-RFLP method. Serum levels of TGF-β1 were significantly increased in breast cancer patients compared to healthy controls (pymph node metastases (p=0.009) remained the only significant independent determinant of high TGF-β1 levels. With regard to prognostic significance for advanced stages (AUC, 0.704) and lymph node metastasis (AUC, 0.683), when the optimal cut-off value was set at 65.15 pg/ml, the sensitivity was 86% and 67%, the specificity was 60% and 62% and accuracy was 66% and 64%, respectively. Survival was shorter in patients with increased serum TGF-β1 (36 months vs 46 months, p=0.022). Multivariate analysis demonstrated a marginal prognostic significance of serum TGF-β1 for survival (p=0.072). The combination of high TGF-β1 and Val-Val genotype predicts a worse prognosis than high serum TGF-β1 alone. Our findings suggest that serum TGF-β1 is involved in tumor malignancy and lymph node metastasis and could be used clinically as a useful tumor marker for evaluation, the extension and the outcome of the disease. They also provide clinical evidence for a significant association between HER-2 Ile655Val SNP and serum TGF-β1, resulting to more aggressive phenotype of the tumor and poor prognosis.

Keywords: serum TGF-beta1, HER-2, polymorphism, breast cancer, survival
Year: 2008, Volume: 55, Issue: 3 Page From: 229, Page To: 238

Price: 24.00 €






© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.